CL2010000413A1 - Anticuerpo monoclonal que reconoce sulfatidos y proteoglicanos sulfatados; composicion farmaceutica que lo comprende; y sus usos para el diagnostico y tratamiento de aterosclerosis. - Google Patents

Anticuerpo monoclonal que reconoce sulfatidos y proteoglicanos sulfatados; composicion farmaceutica que lo comprende; y sus usos para el diagnostico y tratamiento de aterosclerosis.

Info

Publication number
CL2010000413A1
CL2010000413A1 CL2010000413A CL2010000413A CL2010000413A1 CL 2010000413 A1 CL2010000413 A1 CL 2010000413A1 CL 2010000413 A CL2010000413 A CL 2010000413A CL 2010000413 A CL2010000413 A CL 2010000413A CL 2010000413 A1 CL2010000413 A1 CL 2010000413A1
Authority
CL
Chile
Prior art keywords
proteoglycans
atherosclerosis
sulfates
diagnosis
treatment
Prior art date
Application number
CL2010000413A
Other languages
English (en)
Inventor
De Acosta Del Rio Cristina Mateo
Lopez Ana Maria Vazquez
Requena Alejandro Lopez
Marrero Yuniel Fernandez
L Soto
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42355373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of CL2010000413A1 publication Critical patent/CL2010000413A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2010000413A 2009-05-04 2010-04-26 Anticuerpo monoclonal que reconoce sulfatidos y proteoglicanos sulfatados; composicion farmaceutica que lo comprende; y sus usos para el diagnostico y tratamiento de aterosclerosis. CL2010000413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Publications (1)

Publication Number Publication Date
CL2010000413A1 true CL2010000413A1 (es) 2011-02-25

Family

ID=42355373

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000413A CL2010000413A1 (es) 2009-05-04 2010-04-26 Anticuerpo monoclonal que reconoce sulfatidos y proteoglicanos sulfatados; composicion farmaceutica que lo comprende; y sus usos para el diagnostico y tratamiento de aterosclerosis.

Country Status (21)

Country Link
US (1) US8470322B2 (es)
EP (1) EP2428521B1 (es)
JP (1) JP5354823B2 (es)
KR (1) KR101374263B1 (es)
CN (1) CN102414222B (es)
AR (1) AR076495A1 (es)
AU (1) AU2010244859B2 (es)
BR (1) BRPI1013991B1 (es)
CA (1) CA2758994C (es)
CL (1) CL2010000413A1 (es)
CU (1) CU23736A1 (es)
ES (1) ES2656849T3 (es)
HK (1) HK1168362A1 (es)
MX (1) MX2011011665A (es)
MY (1) MY158954A (es)
PE (1) PE20100808A1 (es)
RU (1) RU2502744C2 (es)
SG (1) SG175849A1 (es)
TW (1) TWI424852B (es)
WO (1) WO2010127642A1 (es)
ZA (1) ZA201108832B (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US20020018808A1 (en) 1990-12-10 2002-02-14 Alving Carl R. Vaccines against sterols
US5541296A (en) 1991-08-30 1996-07-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Monocyte adhesion protein and monoclonal antibody thereto
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
JP4315257B2 (ja) * 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
AU721729B2 (en) 1996-05-01 2000-07-13 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
CA2263316A1 (en) 1996-08-14 1998-02-19 Klara Berencsi Methods and compositions for preventing or retarding the development of atherosclerotic lesions
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU3817899A (en) 1998-04-15 1999-11-01 Inserm Therapy of atherosclerosis
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
AR027591A1 (es) 2000-03-03 2003-04-02 Smithkline Beecham Biolog Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno.
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305793D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305790D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
WO2004091520A2 (en) 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
CA2776927C (en) 2004-04-15 2014-08-12 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Also Published As

Publication number Publication date
HK1168362A1 (en) 2012-12-28
AR076495A1 (es) 2011-06-15
PE20100808A1 (es) 2011-01-07
CA2758994C (en) 2015-07-21
EP2428521A1 (en) 2012-03-14
RU2011149252A (ru) 2013-06-10
AU2010244859A1 (en) 2011-12-08
RU2502744C2 (ru) 2013-12-27
KR101374263B1 (ko) 2014-03-13
SG175849A1 (en) 2011-12-29
ES2656849T3 (es) 2018-02-28
BRPI1013991B1 (pt) 2021-08-31
JP5354823B2 (ja) 2013-11-27
US8470322B2 (en) 2013-06-25
MX2011011665A (es) 2012-06-01
AU2010244859B2 (en) 2014-05-29
MY158954A (en) 2016-11-30
KR20120016055A (ko) 2012-02-22
CN102414222B (zh) 2014-07-16
US20120121605A1 (en) 2012-05-17
WO2010127642A1 (es) 2010-11-11
CA2758994A1 (en) 2010-11-11
WO2010127642A9 (es) 2011-03-24
TW201103559A (en) 2011-02-01
CN102414222A (zh) 2012-04-11
BRPI1013991A2 (pt) 2016-04-05
TWI424852B (zh) 2014-02-01
EP2428521B1 (en) 2018-01-03
CU23736A1 (es) 2011-11-15
JP2012526056A (ja) 2012-10-25
ZA201108832B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
CL2014002493A1 (es) Polipeptidos de relaxina modificados; composicion que lo contiene y sus usos (div. sol. 475-2013)
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
BR112012002116A8 (pt) análise pvt de fluídos pressurizados.
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
BRPI1006519A2 (pt) formulação de anticorpos
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI1006922A2 (pt) sistema para descarte de medicação
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BRPI0814644A2 (pt) Anticorpos para cd200 e usos destes na inibição de respostas imunes.
DK2460801T3 (da) Bicyklisk forbindelse samt anvendelse deraf til medicinske formål
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
BRPI1012885A2 (pt) viga e sistema de construção
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0811470A2 (pt) Paralelização de estruturas sequenciais usando transações.
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
CL2014000852A1 (es) Proteína de fusión que comprende dominio extracelular de la proteina humana del receptor humano notch1; composicion que la comprende.
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
BRPI1008977A2 (pt) anticorpo para pcrv humanizado que possui atividade anti-pseudomonal
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
BR112014008339A2 (pt) sistema de cromatografia e utilização de um sistema de cromatografia e da proporção
BR112012021455A2 (pt) formulação farmacêutica ou nutracêutica.
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BR112012002267A2 (pt) compostos para o tratamento de inflamação.